|
June 3, 2020
|
Histogen to Present at BIO Digital 2020
|
|
|
June 1, 2020
|
Histogen Announces First Patient Dosed in Phase 1b/2a Trial of HST 001 for Androgenic Alopecia
|
|
|
May 28, 2020
|
Histogen Appoints Susan A. Knudson as Chief Financial Officer
|
|
|
May 27, 2020
|
Histogen Announces Successful Completion of its Merger with Conatus Pharmaceuticals
|
|
|
May 18, 2020
|
Leading Independent Proxy Advisory Firms Recommend Conatus Pharmaceuticals Shareholders Vote in Favor of its Merger with Histogen and the Required Reverse Stock Split
|
|
|
May 14, 2020
|
Histogen Publishes Preclinical Data on its HST 004 Spinal Disc Program
|
|
|
May 11, 2020
|
Histogen Receives US FDA IND Approval to Initiate Phase 1b/2a Trial of HST 001 in Androgenic Alopecia
|
|
|
May 7, 2020
|
The Conatus Pharmaceuticals Special Meeting of Stockholders Seeking Approval for Proposed Merger with Histogen Inc. will Reconvene on May 21, 2020
|
|
|
May 1, 2020
|
Conatus Pharmaceuticals Reports First Quarter 2020 Financial Results and Strategic Process Update
|
|
|
April 20, 2020
|
Histogen Announces Investigational Device Exemption Application for HST 002
|
|
